Futibatinib + Ivosidenib + Zanidatamab + Trastuzumab + Neratinib + Encorafenib + Binimetinib + Niraparib + Cisplatin + Gemcitabine
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Biliary Tract Neoplasms
Conditions
Biliary Tract Neoplasms
Trial Timeline
Jul 18, 2024 → Jun 1, 2028
NCT ID
NCT05615818About Futibatinib + Ivosidenib + Zanidatamab + Trastuzumab + Neratinib + Encorafenib + Binimetinib + Niraparib + Cisplatin + Gemcitabine
Futibatinib + Ivosidenib + Zanidatamab + Trastuzumab + Neratinib + Encorafenib + Binimetinib + Niraparib + Cisplatin + Gemcitabine is a phase 3 stage product being developed by Zymeworks for Biliary Tract Neoplasms. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05615818. Target conditions include Biliary Tract Neoplasms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05615818 | Phase 3 | Recruiting |
Competing Products
20 competing products in Biliary Tract Neoplasms